​published conference abstract​:

BY : Naser AY. , Bilbisi M. , Mousa R. , Aburmilah A

Delafloxacin is a cost-saving treatment option for patients with ABSSSI in Jordan. Our study findings can help clinicians and decision makers in the healthcare sector prescribe medications for patients with ABSSSI at lower costs while maintaining the efficacy​​

​Introduction Skin and skin structure infections are among the most widespread infectious diseases. Over the past two decades, methicillinresistant Staphylococcus aureus has become a common cause of purulent skin and soft tissue infections. Previous studies demonstrated the non-inferiority of delafloxacin compared to “Piperacillin/Tazobactam + Vancomycin” or “Meropenem + Vancomycin” for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI).​

Objectives The aim of this study was to determine the relative cost difference between delafloxacin and standard of care for the treatment of ABSSI using a cost-minimization analysis in Jordan. Methods We conducted a cost minimization analysis to compare the costs of treating ABSSI with delafloxacin, option A (Piperacillin/ Tazobactam + Vancomycin), and option B (Meropenem + Vancomycin). The cost of medications, the cost of medication administration, and hospitalization costs were calculated as direct costs associated with ABSSSI management. The Jordanian Food and Drug Administration was consulted for information on medication prices. The cost of hospitalization was estimated from four main private hospitals in Jordan. EE636 Acute bacterial skin and skin structure infection (ABSSSI) IV Baxdela for 4 days the

​